Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Related Articles by Review for PubMed (Select 22410709)

1.

The adjuvant treatment of HER2-positive breast cancer.

Jelovac D, Wolff AC.

Curr Treat Options Oncol. 2012 Jun;13(2):230-9. doi: 10.1007/s11864-012-0186-4. Review.

PMID:
22410709
2.

Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.

Chung C, Lam MS.

Am J Health Syst Pharm. 2013 Sep 15;70(18):1579-87. doi: 10.2146/ajhp120735. Review.

PMID:
23988598
3.

Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?

Constantinidou A, Smith I.

Breast. 2011 Oct;20 Suppl 3:S158-61. doi: 10.1016/S0960-9776(11)70316-2. Review.

PMID:
22015286
4.

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.

Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K.

Curr Med Res Opin. 2013 Apr;29(4):405-14. doi: 10.1185/03007995.2013.775113. Epub 2013 Mar 1. Review.

PMID:
23402224
5.

Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing.

Hicks DG, Kulkarni S.

Arch Pathol Lab Med. 2008 Jun;132(6):1008-15. doi: 10.1043/1543-2165(2008)132[1008:TAATFE]2.0.CO;2. Review.

PMID:
18517261
6.

Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.

Corrigan PA, Cicci TA, Auten JJ, Lowe DK.

Ann Pharmacother. 2014 Nov;48(11):1484-93. doi: 10.1177/1060028014545354. Epub 2014 Jul 31. Review.

PMID:
25082874
7.

Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.

Gradishar WJ.

Ann Oncol. 2013 Oct;24(10):2492-500. doi: 10.1093/annonc/mdt217. Epub 2013 Jul 4. Review.

8.

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV.

BMC Cancer. 2007 Aug 8;7:153. Review.

9.

Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

Saini KS, Azim HA Jr, Metzger-Filho O, Loi S, Sotiriou C, de Azambuja E, Piccart M.

Breast. 2011 Oct;20 Suppl 3:S20-7. doi: 10.1016/S0960-9776(11)70289-2. Review.

PMID:
22015288
10.

Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.

O'Sullivan CC, Swain SM.

Expert Opin Biol Ther. 2013 May;13(5):779-90. doi: 10.1517/14712598.2013.783007. Epub 2013 Mar 27. Review.

PMID:
23530718
11.

Current and future anti-HER2 therapy in breast cancer.

Vrbic S, Pejcic I, Filipovic S, Kocic B, Vrbic M.

J BUON. 2013 Jan-Mar;18(1):4-16. Review.

PMID:
23613383
12.

Adjuvant trastuzumab therapy for HER2-positive breast cancer.

Jahanzeb M.

Clin Breast Cancer. 2008 Aug;8(4):324-33. doi: 10.3816/CBC.2008.n.037. Review.

PMID:
18757259
13.

Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.

Cameron DA, Stein S.

Nat Clin Pract Oncol. 2008 Sep;5(9):512-20. doi: 10.1038/ncponc1156. Epub 2008 Jul 1. Review.

PMID:
18594499
14.

Trastuzumab containing regimens for early breast cancer.

Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R.

Cochrane Database Syst Rev. 2012 Apr 18;4:CD006243. doi: 10.1002/14651858.CD006243.pub2. Review.

PMID:
22513938
15.

The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.

Lin A, Rugo HS.

Curr Treat Options Oncol. 2007 Feb;8(1):47-60. Review.

PMID:
17660958
16.

Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.

Garnock-Jones KP, Keating GM, Scott LJ.

Drugs. 2010;70(2):215-39. doi: 10.2165/11203700-000000000-00000. Review. Erratum in: Drugs. 2011 Aug;71(12):1578.

PMID:
20108993
17.

Cardiotoxicity of novel HER2-targeted therapies.

Sendur MA, Aksoy S, Altundag K.

Curr Med Res Opin. 2013 Aug;29(8):1015-24. doi: 10.1185/03007995.2013.807232. Epub 2013 Jun 7. Review.

PMID:
23692263
18.

[Trastuzumab in early breast cancer].

Ismaili N, Elmajjaoui S, Tahri A, Benjaafar N, Errihani H, Belbaraka R.

Presse Med. 2013 Jul-Aug;42(7-8):1069-80. doi: 10.1016/j.lpm.2013.01.054. Epub 2013 Apr 8. Review. French.

PMID:
23578469
19.

Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.

Harbeck N, Wuerstlein R.

Drugs. 2013 Oct;73(15):1665-80. doi: 10.1007/s40265-013-0118-z. Review.

PMID:
24127221
20.

Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.

De Mattos-Arruda L, Cortes J.

Adv Ther. 2013 Jul;30(7):645-58. doi: 10.1007/s12325-013-0043-2. Epub 2013 Jul 24. Review.

PMID:
23881722
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk